MNKD

Insider Trades

Name	Value	Action	Price	Current Price
Binder Steven B.Director $56k16.9k shares SellMay 12, 2026 $3.29 --
Thomson DavidEVP Genl Counsel & Secretary $10.0k3k shares SellMay 12, 2026 $3.29 --
Castagna MichaelDirector, Officer: Chief Executive Officer $259k100k shares BuyMar 10, 2026 $2.59 --
Tross Stuart AChief People & Workpl Officer $298k47k shares SellJan 8, 2026 $6.33 --
Castagna MichaelDirector, Officer: Chief Executive Officer $395k65.8k shares SellDec 17, 2025 $6.01 --
Castagna MichaelDirector, Officer: Chief Executive Officer $128k21.3k shares SellDec 16, 2025 $6.00 --

News

globenewswire.comData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systemsglobenewswire.comJun 5

globenewswire.comData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systemsglobenewswire.comJun 5

globenewswire.comMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPFglobenewswire.comJun 3

seekingalpha.comMannKind At An Inflection Point: Pediatric Expansion Drives The Storyseekingalpha.comJun 2

marketbeat.comMannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Marketmarketbeat.comMay 30

Trade MNKD

About MannKind Corporation

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

CEO: Michael E. Castagna
IPO Date: Jul 28, 2004

Market Data

Open: $4.01
High: $4.02
Low: $3.83
Volume: 11.6M
Avg Volume: 5.9M
52W High: $6.51
52W Low: $2.23

Valuation

Market Cap: $1.2B
Enterprise Value: $1.6B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $14M
Revenue: $349M
Net Income: $5.9M
Cash: $75M
Debt: $473M

Events

EarningsAug 5

EPS est. -0.02